Payment overview · 2025
General Payments
$1,725.63
79 reported records · 14 companies
Healthcare provider profile · identity verified
Don Dongsoo Son, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANAHEIM, CA · NPI 1558564898
Verified facts
What the public records show
CMS Open Payments records show Don Dongsoo Son, MD received $1,725.63 in general payments during 2025 across 79 reported records.
Amgen Inc. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Flector, Jardiance, Licart, Linzess, Ozempic, Prolia, Shingrix, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Flector as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Flector by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Licart as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Licart by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $343.41 | 19.9% | 18 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $327.29 | 19.0% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $168.91 | 9.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $166.10 | 9.6% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $115.90 | 6.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $107.18 | 6.2% | 4 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $99.80 | 5.8% | 5 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $98.71 | 5.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $93.15 | 5.4% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $68.82 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $49.43 | 2.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.96 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.87 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.10 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,725.63 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $327.29 | 17 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $215.59 | 12 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $166.10 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $166.10 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $160.87 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $127.82 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $127.82 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $115.90 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.19 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $101.19 | 4 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $99.80 | 5 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $99.80 | 5 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $99.80 | 5 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $98.71 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.34 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $68.82 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $49.43 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $47.56 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.96 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 224 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 141 | exact normalized | Medicare Part D |
| Flector flector |
2025 | Flector | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| Licart licart |
2025 | Licart | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 137 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 30 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 220 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
224 | 43 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
220 | 50 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
137 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 28 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Flector open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Flector · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Licart open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Licart · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1335 | 274 |
| Losartan Potassium | Losartan Potassium | 749 | 153 |
| Metformin Hcl | Metformin Hcl | 726 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 667 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 570 | 111 |
| Celecoxib | Celecoxib | 549 | 151 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 485 | 97 |
| Vascepa | Icosapent Ethyl | 465 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 404 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 361 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 337 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 336 | 104 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 291 | 87 |
| Metformin Hcl Er | Metformin Hcl | 264 | 54 |
| Donepezil Hcl | Donepezil Hcl | 231 | 36 |
| Creon | Lipase/Protease/Amylase | 224 | 43 |
| Zenpep | Lipase/Protease/Amylase | 220 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 205 | 44 |
| Gabapentin | Gabapentin | 169 | 40 |
| Montelukast Sodium | Montelukast Sodium | 167 | 23 |
| Januvia | Sitagliptin Phosphate | 166 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 166 | 33 |
| Prednisone | Prednisone | 165 | 109 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 161 | 78 |
| Lisinopril | Lisinopril | 145 | 30 |
| Simvastatin | Simvastatin | 145 | 27 |
| Alendronate Sodium | Alendronate Sodium | 141 | 38 |
| Farxiga | Dapagliflozin Propanediol | 141 | 28 |
| Jardiance | Empagliflozin | 140 | 17 |
| Prolia | Denosumab | 137 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 21 |
| Azithromycin | Azithromycin | 129 | 105 |
| Lidocaine | Lidocaine | 113 | 14 |
| Omeprazole | Omeprazole | 110 | 22 |
| Furosemide | Furosemide | 108 | 27 |
| Finasteride | Finasteride | 105 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 29 |
| Icosapent Ethyl | Icosapent Ethyl | 95 | 23 |
| Sertraline Hcl | Sertraline Hcl | 91 | 22 |
| Rybelsus | Semaglutide | 89 | 17 |
| Entresto | Sacubitril/Valsartan | 81 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 15 |
| Torsemide | Torsemide | 75 | 13 |
| Carvedilol | Carvedilol | 74 | 17 |
| Repatha Sureclick | Evolocumab | 73 | suppressed |
| Allopurinol | Allopurinol | 72 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 15 |
| Mupirocin | Mupirocin | 71 | 43 |
| Atenolol | Atenolol | 70 | 14 |
| Valsartan | Valsartan | 70 | 16 |
| Glimepiride | Glimepiride | 68 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 63 | 12 |
| Linzess | Linaclotide | 62 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 61 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 60 | 15 |
| Mirtazapine | Mirtazapine | 59 | 14 |
| Azelastine Hcl | Azelastine Hcl | 57 | 19 |
| Calcitriol | Calcitriol | 57 | suppressed |
| Ciclopirox | Ciclopirox | 54 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 44 |
| Calcium Acetate | Calcium Acetate | 51 | suppressed |
| Famotidine | Famotidine | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 17 |
| Spironolactone | Spironolactone | 48 | suppressed |
| Myrbetriq | Mirabegron | 46 | 11 |
| Fluocinonide | Fluocinonide | 42 | 13 |
| Folic Acid | Folic Acid | 42 | 17 |
| Ketoconazole | Ketoconazole | 42 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 37 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 13 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | 23 |
| Eliquis | Apixaban | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Proctozone-Hc | Hydrocortisone | 33 | suppressed |
| Baclofen | Baclofen | 31 | 15 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 31 | 25 |
| Licart | Diclofenac Epolamine | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 26 | 11 |
| Vemlidy | Tenofovir Alafenamide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 24 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 17 |
| Valacyclovir | Valacyclovir Hcl | 23 | 17 |
| Estradiol | Estradiol | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Flector | Diclofenac Epolamine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 16 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,725.63 · 79 records | Amgen Inc. | AIRSUPRA, AREXVY, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, Flector, JARDIANCE, LEQVIO, LINZESS, Licart, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, PROLIA, REPATHA, REXULTI, SHINGRIX, Tirosint, VERQUVO, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error